Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2010 | 5 | 4 | 426-430
Tytuł artykułu

Combined treatment and survival of medullary thyroid carcinoma patients

Treść / Zawartość
Warianty tytułu
Języki publikacji
The aim of this study is to analyze the impact of combined treatment (thyroidectomy and radiotherapy and radioactive iodine treatment) on patients’ long-term survival with medullary thyroid carcinoma. This is a retrospective study of 59 patients treated from 1977 to 2006 for medullary carcinoma at the Institute of Oncology in Vilnius, Lithuania. Survival was estimated by the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard models were used to explore the association of prognostic factors with long-term survival. The survival of MTC patients was 88.0% (95% CI 68.0–88.9), 67.9% (95% CI 52.3–79.4) and 60.5% (95% CI 43.2–74.0), respectively, 5, 10 and 15 years after diagnosis. In survival analysis, only the type of surgery and lymph node involvement were found to be significant prognostic factors. The results of this study suggest that treatment with radioiodine and external beam radiotherapy do not improve significantly the long-term survival of surgically treated MTC patients.

Opis fizyczny
  • Institute of Oncology, Vilnius University, Clinic of conservative tumour therapy, Santariskiu 1, LT-08660, Vilnius, Lithuania
  • Institute of Oncology, Vilnius University, Clinic of conservative tumour therapy, Santariskiu 1, LT-08660, Vilnius, Lithuania
  • Institute of Oncology, Vilnius University, Scientific Research Centre, P. Baublio 3B, LT-08406, Vilnius, Lithuania,
  • [1] Cohen M.S., Molley J.F., Surgical treatment of medullary thyroid carcinoma, J. Intern. Med., 2003, 253, 616–626[Crossref]
  • [2] Yen T.W., Shapiro S.E., Gagel R.F., Sherman S.I., Lee J.E., Evans D.B., Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients, Surgery, 2003, 134, 890–899[Crossref]
  • [3] Ball D.W., DeBustos A.C., Thyroid, 8th ed., Philadelphia, Lippincott Williams & Wilkins, 2000
  • [4] Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., et al., Medullary thyroid cancer: management guidelines of American Thyroid Association, Thyroid, 2009, 19, 565–612[WoS][Crossref]
  • [5] Bergholm U., Bergstrom R., Ekbom A., Long-term follow-up of patients with medullary carcinoma of the thyroid, Cancer, 1997, 79, 132–138<132::AID-CNCR19>3.0.CO;2-5[Crossref]
  • [6] de Groot J.W., Plukker J.T., Wolffenbuttel B.H., Wiggers T., Sluiter W.J., Links T.P., Determinants of life expectancy in medullary thyroid cancer: age does not matter, Clin. Endocrinol., 2006, 65, 729–736[Crossref]
  • [7] Roman S., Lin R., Sosa J.A., Prognosis of medullary thyroid carcinoma, Cancer, 2006, 107, 2134–2142[Crossref]
  • [8] Cupisti K., Wolf A., Raffel A., Schott M., Miersch D., Yang Q., et al., Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years, Ann. Surg., 2007, 246, 815–821[Crossref]
  • [9] Rendl G., Manzl M., Hitzl W., Sungler P., Pirich C., Long-term prognosis of medullary thyoid carcinoma, Clin. Endocrinol., 2008, 69, 497–505
  • [10] Scollo C., Baudin E., Travagli J.P., Caillou B., Bellon N., Leboulleux S., et al., Rationale for central and bilateral lymph node dissection in sporadic hereditary medullary thyroid cancer, J. Clin. Endocrinol. Metab., 2003, 88, 2070–2075[Crossref]
  • [11] Moley J.F., DeBenedetti M.K., Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extend of node dissection, Ann. Surg., 1999, 229, 880–887
  • [12] Leboulleux S., Baudin E., Travagli J.P., Schlumberger M., Medullary thyroid carcinoma, Clin. Endocrinol., 2004, 61, 299–310
  • [13] Pelizzo M.R., Boschin I.M., Bernante P., Toniato A., Piotto A., Pagetta C., et al., Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients, Eur. J. Surg. Oncol., 2007, 33, 493–497[Crossref]
  • [14] Schwartz D.L., Rana V., Shaw S., Yazbeck C., Ang K.K., Morrison W.H., et al., Post radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era, Head Neck, 2008, 883–888
  • [15] Tubiana M., Haddad E., Schlumberger M., Hill C., Rougier P., Sarrazin D., External radiotherapy in thyroid cancer, Cancer, 1985, 55, 2062–2071<2062::AID-CNCR2820551406>3.0.CO;2-O[Crossref]
  • [16] Schlumberger M., Gardet P., External radiotherapy and chemotherapy in MTC patients, In: Calmettes C., Guliana J., M., (Eds.), Medullary Thyroid Carcinoma, Colloques INSERM/John Libbey Eurotext Ltd, 1991
  • [17] Brierley J., Tsang R., Simpson W.J., Gospodarowicz M., Sutcliffe S., Panzarella T., Medullary thyroid cancer: analyses of survival and prognostic factors the role of radiation therapy in local control, Thyroid, 1996, 6, 305–310[Crossref]
  • [18] Fife K.M., Bower M., Harmer C.L., Medullary thyroid cancer: the role of radiotherapy in local control, Eur. J. Surg. Oncol., 1996, 22, 588–591[Crossref]
  • [19] Fersht N., Vini L., A’Hern R., Harmer C., The role of radiothrepy in the management of elevated calcitonin after surgery for medullary thyroid cancer, Thyroid, 2001, 11, 1161–1168[Crossref]
  • [20] Hellman D.E., Kartchner M., Van Antwerp J.D., Salmon S.E., Patton D.D., O’Mara R., Radioiodine in the treatment of medullary carcinoma of the thyroid, J. Clin. Endocrinol. Metab., 1979, 48, 451–455[Crossref]
  • [21] Deftos L.J., Stein M.F., Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma, J. Clin. Endocrinol. Metab., 1980, 50, 967–968[Crossref]
  • [22] Finny P., Jacob J.J., Thomas N., Philip J., Rajarathnam S., Oommen R. et al., Medullary thyroid carcinoma: a 20-year experience from centre in South India. ANZ J. Surg., 2007, 77, 130–134[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.